ARNI mainly focuses on inhibiting the activity of neprilysin to decrease the degradation of natriuretic peptides, stimulate vasodilation and diuresis, and reduce myocardial fibrosis and hypertrophy, which has shown clinical benefits in HF with HFrEF (Pascual-Figal et al., 2021). This evidence concerns the gene MME and cardiac hypertrophy.